See what others are saying about TransIT®-2020 Transfection Reagent...
"I recently tested TransIT®-2020 and TransIT®-LT1, and both reagents worked well in terms of their efficiency at transfecting human-derived iPS cells with CRISPR constructs and a fluorescent protein reporter. Through visual inspection, transfection efficiencies with TransIT®-2020 and TransIT®-LT1 were clearly higher than with Lipofectamine® 3000."
- Fedir Kiskin, University of Cambridge
"Our lab routinely works with primary human fibroblasts which are notoriously difficult to transfect, and we require a method that is non-toxic, reliable, and reproducible. TransIT®-2020 is the only reagent on the market that fits those criteria. In addition, TransIT®-2020 also transfects colon cancer cell lines HCT-116 and DLD1 with much higher efficiencies. Overall, the pace and quality of our research have improved since we started using TransIT®-2020."
- John A. Burns, David Scicchitano Lab, New York University
"...We have been able to transfect BMDM’s with the TransIT®-2020 Transfection Reagent. Not only are my cells healthier, but I get good expression, and it is more cost effective to the Neon Transfection System that my lab traditionally uses. I have also been able to share these results with others that are now trying it with great success. It makes me look like a hero!"
- Jeffrey Fay, Hoffman Lab, University of Hawaii at Manoa
"…However, I did find a gem: The TransIT®-2020 reagent from Mirus Bio LLC. I tested five or six breast cancer cell lines, and in general, my transfection efficiency was 5-10 fold higher with the TransIT®-2020reagent than with the 'standards' - Lipofectamine®...with essentially no cell death. I also saw, for the first time ever, true 100% transfection efficiency of HEK293 cells - every last cell on the plate, glowing bright GFP-green."
- Nicole Perry, Kontrogianni Lab, University of Maryland
"TransIT®-2020 Transfection Reagent has been working well in our CRISPR genome editing experiments in HEK 293 cells. I appreciate the fact that the transfection protocol is straightforward, the toxicity appears to be low and we obtained high CRISPR knockout efficiency."
- Steve Plouffe, Sanford Consortium for Regenerative Medicine
Preliminary Data: Western blot from non-clonal cell populations demonstrating efficient targeting of three genes of interest.